Ariad Pharmaceuticals Inc.

Among 8 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 0 have Buy rating, 1 Sell and 7 Hold. Therefore 0 are positive. Ariad Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Underweight” rating by Barclays Capital given on Tuesday, ...

William Blair reissued their outperform rating on shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) in a research note released on Friday. William Blair currently has a $15.00 price target on the pharmaceutical company's stock, up from their previous price target of $12.00.

Ariad Pharmaceuticals Inc. logo JMP Securities downgraded shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) from an outperform rating to a market perform rating in a research report released on Tuesday. JMP Securities currently has $9.37 target price on the pharmaceutical company's stock, up from ...

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)'s stock had its “outperform” rating reissued by stock analysts at Leerink Swann in a research report issued to clients and investors on Wednesday. They currently have a $20.00 price objective on the pharmaceutical company's stock. Leerink Swann's target price ...

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)'s stock had its “outperform” rating restated by Cowen and Company in a research report issued to clients and investors on Saturday. They currently have a $16.00 price target on the pharmaceutical company's stock, up from their previous price target of $10.00.

Cascadian Therapeutics (NASDAQ: CASC) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ...

The latest market report published by Credence Research, Inc. “Global Chronic Myeloid Leukemia (CML) Tretament Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023,” the chronic myeloid leukemia (CML) treatment market was valued at USD 2,828.9 Mn in 2015, and ...

Among 8 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 0 have Buy rating, 1 Sell and 7 Hold. Therefore 0 are positive. Ariad Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was initiated by Barclays Capital with “Underweight” on Tuesday, ...

Companies profiled in this report include: Abbvie Inc., Adaptimmune, Aduro Biotech, Advantagene, Advaxis Immunotherapies, Amgen, Argos Therapeutics, Ariad Pharmaceuticals, Arog Pharmaceuticals, Aserta Pharmaceuticals, Astellas, Astrazeneca, Avax Technologies, Bavarian Nordic, Bayer Healthcare, ...

Clackson most recently served as president of research and development at ARIAD Pharmaceuticals until its acquisition by Takeda. He led the research and development team that discovered and brought to market two innovative targeted therapies for cancer and moved three additional medicines into ...

Takeda Pharmaceutical acquired a US oncology firm for about 5 billion dollars last year to speed up development of anti-cancer drugs. Ariad Pharmaceuticals is known for its leukemia and lung cancer medicines. America's Pfizer has also acquired Medivation with a promising cancer drug for about 14 ...

Auris Medical (NASDAQ: EARS) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst ...

Germano, Panayiotopoulos and Schlesinger have all been involved with other companies Denner's invested in, two of which Denner – a Carl Icahn protege – ultimately orchestrated the sale of: Bioverativ and Ariad Pharmaceuticals. "As a result of the rapid and significant evolution our business and the ...

Auris Medical (NASDAQ: EARS) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst ...

Early last year, Takeda paid $5.2 billion for Ariad Pharmaceuticals Inc. of Cambridge, which has a blood cancer drug on the market. Shire had drawn interest from other drug makers, too. In 2014, its chief executive, Flemming Ornskov, fought off a proposed takeover by AbbVie Inc. Last week, as Takeda ...

A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Ariad Pharmaceuticals Inc (NASDAQ: ARIA) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on April 26, 2018 and NASDAQ: ARIA investors should contact the ...

Some of the major companies operating in the global oncology drugs market are Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer and ...